8.76
-0.3(-3.31%)
Currency In USD
| Previous Close | 9.06 |
| Open | 8.95 |
| Day High | 9.29 |
| Day Low | 8.68 |
| 52-Week High | 12.19 |
| 52-Week Low | 2.32 |
| Volume | 798,875 |
| Average Volume | 646,455 |
| Market Cap | 474.02M |
| PE | -7.68 |
| EPS | -1.14 |
| Moving Average 50 Days | 9.3 |
| Moving Average 200 Days | 6.55 |
| Change | -0.3 |
If you invested $1000 in Fulcrum Therapeutics, Inc. (FULC) since IPO date, it would be worth $648.89 as of December 04, 2025 at a share price of $8.76. Whereas If you bought $1000 worth of Fulcrum Therapeutics, Inc. (FULC) shares 5 years ago, it would be worth $746.8 as of December 04, 2025 at a share price of $8.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
GlobeNewswire Inc.
Dec 02, 2025 1:30 PM GMT
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 9:45 PM GMT
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
GlobeNewswire Inc.
Oct 22, 2025 12:54 PM GMT
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defin